These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Biological Characterization of Conserved Residues within the Cytoplasmic Tail of the Pichinde Arenaviral Glycoprotein Subunit 2 (GP2). Shao J; Huang Q; Liu X; Di D; Dileepan M; Brisse M; Ly H; Liang Y J Virol; 2019 Nov; 93(22):. PubMed ID: 31462569 [TBL] [Abstract][Full Text] [Related]
23. Current research for a vaccine against Lassa hemorrhagic fever virus. Warner BM; Safronetz D; Stein DR Drug Des Devel Ther; 2018; 12():2519-2527. PubMed ID: 30147299 [TBL] [Abstract][Full Text] [Related]
35. Identification of protective Lassa virus epitopes that are restricted by HLA-A2. Botten J; Alexander J; Pasquetto V; Sidney J; Barrowman P; Ting J; Peters B; Southwood S; Stewart B; Rodriguez-Carreno MP; Mothe B; Whitton JL; Sette A; Buchmeier MJ J Virol; 2006 Sep; 80(17):8351-61. PubMed ID: 16912286 [TBL] [Abstract][Full Text] [Related]
36. Vaccine platforms for the prevention of Lassa fever. Purushotham J; Lambe T; Gilbert SC Immunol Lett; 2019 Nov; 215():1-11. PubMed ID: 31026485 [TBL] [Abstract][Full Text] [Related]
37. The antifungal isavuconazole inhibits the entry of lassa virus by targeting the stable signal peptide-GP2 subunit interface of lassa virus glycoprotein. Zhang X; Tang K; Guo Y Antiviral Res; 2020 Feb; 174():104701. PubMed ID: 31877348 [TBL] [Abstract][Full Text] [Related]